8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

June 6, 2024

Date of Report (date of earliest event reported)

Ekso Bionics Holdings, Inc.

(Exact name of registrant as specified in its charter)

(510) 984-1761

Registrant's telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ****

☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 6, 2024, Ekso Bionics Holdings, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the "Annual Meeting").

Of the 18,099,260 shares of common stock outstanding and entitled to vote at the Annual Meeting, 11,425,241 shares were present at the Annual Meeting either virtually or by proxy, constituting a quorum. The stockholders voted on the following proposals at the Annual Meeting:

For more information about the foregoing proposals, see the Company’s proxy statement, filed with the Securities and Exchange Commission on April 26, 2024.

The voting results for each of the proposals are as follows:

Each director nominee was duly elected to serve until the 2025 annual meeting of stockholders and until his or her successor is duly elected and qualified, subject to earlier resignation or removal.

The stockholders approved the extension of the term of the Company’s Amended and Restated 2014 Equity Incentive Plan to until April 15, 2034 and the establishment of the total number of shares of common stock authorized for issuance pursuant to awards granted thereunder to 4,724,286 (an increase in the total number of shares of common stock authorized for issuance pursuant to awards of 1,000,000 as compared to the total number of shares of common stock authorized for issuance pursuant to awards under the Company’s Amended and Restated 2014 Equity Incentive Plan prior to its expiration).

The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.

The stockholders approved, on an advisory basis, the future advisory vote on compensation of the Company’s named executive officers to occur annually.

The stockholders ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.